Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma | Biomarker Research | Full Text

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma | Biomarker Research | Full Text

Biomarker Research

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma

• Amandeep Aujla,
• Ravijot Aujla and
• Delong LiuEmail authorView ORCID ID profile

Biomarker Research20197:9

https://doi.org/10.1186/s40364-019-0160-4

©  The Author(s). 2019

• Received: 18 February 2019
• Accepted: 27 March 2019
• Published: 11 April 2019

Abstract

B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell surfaces. Immunotherapeutic agents including antibodies and chimeric antigen receptor T cells are widely studied in clinical trials. Several antibody-drug conjugates (ADC) have been approved for clinical use (gemtuzumab ozogamicin in acute myeloid leukemia and brentuximab vedotin in Hodgkin lymphoma as well as CD30+ anaplastic large cell lymphoma). Inotuzumab ozogamicin (INO), a CD22 antibody conjugated with calicheamicin is one of the newest ADCs. INO has been approved for treatment of relapsed /refractory B cell precursor ALL. Multiple ongoing trials are evaluating its role in the relapsed /refractory B cell NHL. This review summarized recent development in INO applications for ALL and NHL.

Keywords

• Acute lymphoblastic leukemia
• CD22
• Inotuzumab ozogamicin
• Non-Hodgkin lymphoma
• Antibody-drug conjugate
• ADC